Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

The company is awaiting U.S. Food and Drug Administration approval to begin a similar research trial in the United States with 350 patients whose high blood pressure isn’t controlled by medication. The company already has permission to do the procedure in Europe, and will begin commercializing it early in 2011, Cleeland said.

Future research will also explore the potential benefit of the Symplicity Catheter System on diabetes, after a pilot study suggested that destroying the nerves also improved clinical markers of diabetes.

Randall Zusman, director of the division of hypertension at the Massachusetts General Hospital Heart Center, questions how big the potential market really is. He says only a handful of his 3,000 current patients are as drug-resistant as the patients in Esler’s research. “When you make a concerted effort—five drugs or more—you’re going to get most people under control,” Zusman says.

But both Zusman and Aram Chobanian, a hypertension expert at Boston University, say they were impressed by the size of the drop in blood pressure, and look forward to seeing more research.

“The effects on blood pressure are quite remarkable,” says Chobanian. No existing drug has done more to lower blood pressure, he says. “The initial data provided here are very impressive.”

0 comments about this story. Start the discussion »

Credit: Ardian

Tagged: Biomedicine, drugs, blood, medical devices, surgery, blood pressure

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me